The healthcare industry, often referred to as 'Big Medicine,' has become a complex web of middlemen, each with their own agenda, threatening both our wallets and our well-being. However, there is a growing movement to address this issue, and it's about time.
The Problem with Big Medicine
Pharmacy Benefit Managers (PBMs) are a prime example of the dysfunction within the system. These middlemen, who negotiate drug prices, have been accused of steering patients towards expensive medications and charging exorbitant fees. The New York Times even reported on their counterintuitive practices, highlighting how they often increase, rather than reduce, drug costs.
The spending bill passed earlier this year aimed to limit some of these practices, but it's just a drop in the ocean. The real issue lies with the entire 'Big Medicine' ecosystem, which includes insurance conglomerates and wholesale drug distributors, all of whom contribute to skyrocketing healthcare costs and the demise of independent providers.
What makes this particularly fascinating is the contrast between the quality of healthcare Americans receive and the costs they incur. Despite facing the highest medical costs in the world, the quality of care is only average at best. This is a clear indication that something is deeply wrong with the system.
Profits Over Patients
Six of the country's most valuable companies are from the healthcare sector, generating billions in profits annually. This profit-centric model often takes precedence over patient care, with Big Pharma abusing patents to keep drug costs high and block competition from more affordable generics.
The 'big three' PBMs, which control a staggering 80% of U.S. prescriptions, are a prime example of this. They are vertically integrated with major insurance conglomerates and pharmacies, leveraging their market power to drive up drug costs and push out independent pharmacies.
Drug wholesalers, like McKesson, Cencora, and Cardinal Health, are also part of this problematic vertical integration. They control 96% of U.S. drug distribution and, like PBMs, are increasingly integrated with medical providers, creating conflicts of interest. For instance, a subsidiary of Cencora agreed to pay $1 million to resolve allegations of paying kickbacks to healthcare providers, influencing the choice of drugs for patients.
The Need for Reform
Efforts to reform PBMs have faced fierce opposition from industry groups, with even Elon Musk getting involved, albeit unknowingly. Despite these challenges, lawmakers were able to include some PBM reforms in a spending bill passed earlier this year.
However, these reforms are just a start. Policymakers are now broadening their focus, with states like Arkansas and Tennessee passing laws to prohibit PBMs from owning pharmacies. Research suggests that such bans could reduce drug prices significantly.
A Call for Action
The Break Up Big Medicine Act, introduced by Senators Elizabeth Warren and Josh Hawley, aims to prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers. This would effectively break up the six largest Big Medicine companies, potentially lowering healthcare costs and promoting competition.
Public support for such legislation is growing, with a recent poll showing that a vast majority of voters believe health insurance companies have too much control and drive up costs. Business leaders like Mark Cuban also endorse breaking up these companies.
In my opinion, this act is a necessary step towards reforming the U.S. healthcare system. While it may not solve all the problems, it's a crucial step towards a more equitable and efficient healthcare system. Just as the Glass-Steagall Act separated commercial and investment banks during the Great Depression, we need similar structural reforms to address the catastrophic threat posed by Big Medicine.
